NSCLC metastatic/molecular target

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 08/09/2022)

AKT mutation
Currently no open trials

ALK fusion
Currently no open trials

BRAF mutation
TAPISTRY (Roche)
Tumor-Agnostic Precision Somatic Targeting for Class II or III BRAF mutation with Belvarafenib. 
(contact datanursingreo@uzleuven.be to check whether one of the cohorts is open)
 
EGFR common exon 19 or exon 21 mutation
FLOSI (Academic) (1st line) 
Local AblativeTherapy for Oligoprogressive EGFRm Non-Small-Cell Lung Cancer Treated on First-line OSImertinib.

MARIPOSA-2 (Janssen) (2nd line) 
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure.

EGFR exon 20 insertion mutation
PAPILLON (Janssen) (1st line) 
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

HER2 mutation
DESTINY-LUNG04 (Astra Zeneca) (1st line) - exon 19 and 20 mutation
An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations

ZENITH20 (Spectrum) (2nd line) - exon 20 mutation
A Phase 2 Study of Poziotinib in Patients with Non-small cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with HER2 Exon 20 Insertion Mutation.
(only cohort 5 open)

KRAS G12C mutation
CJDQ443A12101 (Novartis) (2nd and 3rd line) Combination therapy after prior KRAS G12C inhibitor.
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation.
(contact datanursingreo@uzleuven.be to check whether one of the cohorts is open)

BI1823911 (Boehringer) (end-line)
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation. 
(contact datanursingreo@uzleuven.be to check whether one of the cohorts is open)

MET
Currently no open trials

NRG1 fusion
MCLA-128-CL01 (Merus) (any line)
A Phase I/II Study of Zenocutuzumab (MCLA-128), a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors.

NTRK fusion
TRIDENT-1 (TurningPoint)  (1st, 2nd and 3rd line)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring NTRK1-3 Rearrangements.

PIK3CA mutation
TAPISTRY (Roche) (1st and 2nd line)
Tumor-Agnostic Precision Somatic Targeting PIK3CA with Inavolisib (GDC-0077).

RET fusion
Currently no open trials

ROS1 fusion
TRIDENT-1 (TurningPoint) (1st, 2nd and 3rd line)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ROS1 Rearrangements.

3rd line (all mutations)
ImmunoSABR (Academic)
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.